Opinion Article
Ongoing COVID-19 Clinical Trials: A Pharmacological Perspective on Pneumonia
Prof. Dr. Amani E Khalifa 1* and Asser I Ghoneim2
1Professor of Pharmacology & Toxicology, Faculty of Pharmacy, Ain Shams University currently seconded to the Children Cancer Hospital in Egypt 57357 (CCHE 57357) as the Pharmacy Consultant.
2Professor, Department of Pharmacology & Toxicology, Damanhour University, Egypt
Prof. Dr. Amani E Khalifa, Professor of Pharmacology & Toxicology, Faculty of Pharmacy, Ain Shams University currently seconded to the Children Cancer Hospital in Egypt 57357 (CCHE 57357) as the Pharmacy Consultant.
Received Date: November 26, 2020; Published Date: December 14, 2020
Abstract
COVID-19 is an ongoing global pandemic of coronavirus disease 2019 as an atypical type of viral pneumonia caused by severe acute respiratory syndrome coronavirus 2 (SARS CoV 2). Many potential pharmacological agents are currently being investigated against this disease. This article points to, and justifies, the importance of investigating the potential pharmacotherapies for COVID-19 “pneumonia”, rather than the broad category of COVD-19 disease, or COVID-19 associated acute respiratory distress syndrome (ARDS).
Keywords: COVID-19; Trials, Pharmacotherapy; Perspective; Pneumonia
-
Amani E Khalifa, Asser I Ghoneim. Ongoing COVID-19 Clinical Trials: A Pharmacological Perspective on Pneumonia. Curr Tr Clin & Med Sci. 2(2): 2020. CTCMS.MS.ID.000533.
-
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.